{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:53:09Z","timestamp":1782219189963,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"DOI":"10.7759\/cureus.111353","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:21:18Z","timestamp":1782217278000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological Management and Longitudinal Cognitive, Psychiatric, and Behavioral Changes During Stem Cell Therapy in a Patient With Mesial Temporal Sclerosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Eduardo","family":"Ciarrochi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Bautista","family":"Ciarrochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Adrian","family":"Ugartemend\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Polypharmacy in psychiatry: a review","volume":"11","author":"Kukreja S","year":"2013","unstructured":"Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013, 11:82-99.","journal-title":"Mens Sana Monogr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190017699138","article-title":"Comorbidity, polytherapy, and drug interactions in a neurological context: an example of a multidisciplinary approach to promote the rational use of drugs","volume":"31","author":"Busa G","year":"2018","unstructured":"Busa G, Burlina A, Damuzzo V, Chiumente M, Palozzo AC. Comorbidity, polytherapy, and drug interactions in a neurological context: an example of a multidisciplinary approach to promote the rational use of drugs. J Pharm Pract. 2018, 31:58-65. 10.1177\/0897190017699138","journal-title":"J Pharm Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2019.0052","article-title":"Antipsychotic drugs in epilepsy","volume":"53","author":"G\u00f3rska N","year":"2019","unstructured":"G\u00f3rska N, S\u0142upski J, Cuba\u0142a WJ. Antipsychotic drugs in epilepsy. Neurol Neurochir Pol. 2019, 53:408-12. 10.5603\/PJNNS.a2019.0052","journal-title":"Neurol Neurochir Pol"},{"key":"ref4","article-title":"Mesial temporal sclerosis in paediatrics: its clinical spectrum. Our experience gained over a 19-year period [Article in Spanish]","volume":"50","author":"Monge-Galindo L","year":"2010","unstructured":"Monge-Galindo L, P\u00e9rez-Delgado R, L\u00f3pez-Pis\u00f3n J, Lafuente-Hidalgo M, del Olmo-Izuzquiza IR, Pe\u00f1a-Segura JL. Mesial temporal sclerosis in paediatrics: its clinical spectrum. Our experience gained over a 19-year period [Article in Spanish]. Rev Neurol. 2010, 50:341-8.","journal-title":"Rev Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/751510","article-title":"Temporal lobe epilepsy semiology","volume":"2012","author":"Blair RD","year":"2012","unstructured":"Blair RD. Temporal lobe epilepsy semiology. Epilepsy Res Treat. 2012, 2012:751510. 10.1155\/2012\/751510","journal-title":"Epilepsy Res Treat"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s42494-024-00172-5","article-title":"Mesial temporal sclerosis and epilepsy: a narrative review","volume":"6","author":"Villamizar-Torres D","year":"2024","unstructured":"Villamizar-Torres D, Cepeda Trillos AC, Vargas-Moreno A. Mesial temporal sclerosis and epilepsy: a narrative review. Acta Epileptol. 2024, 6:28. 10.1186\/s42494-024-00172-5","journal-title":"Acta Epileptol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-025-09191-5","article-title":"Ammonia reduces glutamine synthetase expression in astrocytes via activation of Hippo-YAP signaling pathways","volume":"8","author":"Nasu Y","year":"2025","unstructured":"Nasu Y, Kishikawa S, Imai M, Yokoyama N, Iida I, Tabeta K, Terunuma M. Ammonia reduces glutamine synthetase expression in astrocytes via activation of Hippo-YAP signaling pathways. Commun Biol. 2025, 8:1810. 10.1038\/s42003-025-09191-5","journal-title":"Commun Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1183775","article-title":"Astrocytes as a target for therapeutic strategies in epilepsy: current insights","volume":"16","author":"\u00c7ar\u00e7ak N","year":"2023","unstructured":"\u00c7ar\u00e7ak N, Onat F, Sitnikova E. Astrocytes as a target for therapeutic strategies in epilepsy: current insights. Front Mol Neurosci. 2023, 16:1183775. 10.3389\/fnmol.2023.1183775","journal-title":"Front Mol Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00281","article-title":"The role and regulatory mechanism of Hippo signaling components in the neuronal system","volume":"11","author":"Cheng J","year":"2020","unstructured":"Cheng J, Wang S, Dong Y, Yuan Z. The role and regulatory mechanism of Hippo signaling components in the neuronal system. Front Immunol. 2020, 11:281. 10.3389\/fimmu.2020.00281","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/09636897231158967","article-title":"Stem cells: recent developments redefining epilepsy therapy","volume":"32","author":"Alayli A","year":"2023","unstructured":"Alayli A, Lockard G, Gordon J, et al.. Stem cells: recent developments redefining epilepsy therapy. Cell Transplant. 2023, 32:9636897231158967. 10.1177\/09636897231158967","journal-title":"Cell Transplant"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0023-5","article-title":"Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases","volume":"14","author":"Shi Y","year":"2018","unstructured":"Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, Wang Y. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018, 14:493-507. 10.1038\/s41581-018-0023-5","journal-title":"Nat Rev Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cells11244129","article-title":"Therapeutic potential of mesenchymal stem cells in the treatment of epilepsy and their interaction with antiseizure medications","volume":"11","author":"Tesiye MR","year":"2022","unstructured":"Tesiye MR, Gol M, Fadardi MR, Kani SN, Costa AM, Ghasemi-Kasman M, Biagini G. Therapeutic potential of mesenchymal stem cells in the treatment of epilepsy and their interaction with antiseizure medications. Cells. 2022, 11:4129. 10.3390\/cells11244129","journal-title":"Cells"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-018-0429-1","article-title":"Regenerative abilities of mesenchymal stem cells through mitochondrial transfer","volume":"25","author":"Paliwal S","year":"2018","unstructured":"Paliwal S, Chaudhuri R, Agrawal A, Mohanty S. Regenerative abilities of mesenchymal stem cells through mitochondrial transfer. J Biomed Sci. 2018, 25:31. 10.1186\/s12929-018-0429-1","journal-title":"J Biomed Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.596287","article-title":"Multipronged attack of stem cell therapy in treating the neurological and neuropsychiatric symptoms of epilepsy","volume":"12","author":"Sadanandan N","year":"2021","unstructured":"Sadanandan N, Saft M, Gonzales-Portillo B, Borlongan CV. Multipronged attack of stem cell therapy in treating the neurological and neuropsychiatric symptoms of epilepsy. Front Pharmacol. 2021, 12:596287. 10.3389\/fphar.2021.596287","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2012.00359","article-title":"Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy","volume":"3","author":"Baglio SR","year":"2012","unstructured":"Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol. 2012, 3:359. 10.3389\/fphys.2012.00359","journal-title":"Front Physiol"},{"key":"ref16","article-title":"Psychopharmacology Treaty: Bases and Clinical Application","author":"Vallejo MS","year":"2009","unstructured":"Vallejo MS, Rodrigo CP, Ruiz JP. Psychopharmacology Treaty: Bases and Clinical Application. Pan American Doctor, Madrid, Spain; 2009."},{"key":"ref17","unstructured":"Biperideno. (2020). Accessed. May 20, 2026: https:\/\/www.aeped.es\/comites\/cm\/pediamecum\/principios-activos\/biperideno."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503214-pharmacological-management-and-longitudinal-cognitive-psychiatric-and-behavioral-changes-during-stem-cell-therapy-in-a-patient-with-mesial-temporal-sclerosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:21:26Z","timestamp":1782217286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503214-pharmacological-management-and-longitudinal-cognitive-psychiatric-and-behavioral-changes-during-stem-cell-therapy-in-a-patient-with-mesial-temporal-sclerosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.111353","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}